- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00475475
Sweetened Beverages and Food Intake
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The rise in the prevalence of obesity and type 2 diabetes mellitus has been linked to an increased consumption of sugar- and particularly fructose-sweetened beverages. Preliminary evidence suggests that this could be partly explained by the fact that the reduction in the intake of solid food is inadequate to compensate for additional energy taken up from these beverages. In addition, the type of sugar used to sweeten a beverage might have a considerable impact on the body's ability to adjust food intake properly. In particular, the consumption of fructose has been reported to reduce diurnal plasma glucose, insulin, and leptin concentrations, but increase diurnal ghrelin concentrations as compared to isocaloric amounts of glucose. As the plasma concentrations of glucose, insulin, leptin, and ghrelin are involved in the regulation of food intake and energy expenditure, this might impair the longer-term ability of the body to match food intake and energy expenditure to stabilize body weight.
To investigate whether the regular consumption of fructose-sweetened beverages leads to an increase in total energy intake, the investigators will enroll healthy normal-weight subjects into a controlled diet study using a double-blind randomized cross-over design. Each subject will complete three diet periods: solid food plus a beverage sweetened with fructose (A), solid food plus a beverage sweetened with glucose (B), solid food plus a beverage sweetened with a non-caloric sweetener (C). During each period, subjects will be provided with all their food for 8 days. These diets will consist of meals freshly prepared using regular food items typically found in the American diet. Solid food will be provided in excess of what the subjects are estimated to require. Subjects will be asked to eat as much of this food as they need to feel comfortably satiated, and to return all excess foods to the Nutrition Research Kitchen of the University of Washington (UW) General Clinical Research Center (GCRC). This returned food will be weighed to assess precisely the amount and type of food eaten by the subjects on each day of these diet periods. In addition to this solid food, subjects will be asked to drink a certain amount of a lemonade sweetened with either fructose (A), glucose (B), or a non-caloric sweetener (C). In groups A and B, the subjects will consume 25% of their estimated daily calorie requirement in the form of these sugar sweetened beverages, while the drink in period C will be of the same volume.
Subjects will be admitted to the GCRC on the morning of day 9 of each diet period for the measurement of resting metabolic rate by means of indirect calorimetry and blood draws for the measurement of fasting plasma concentrations of adipogenic hormones and plasma lipids. Furthermore, we will administer a standardized breakfast and draw blood before and 0, 15, 30, 60, 90, and 120 minutes after this meal to measure the postprandial plasma concentrations of insulin, ghrelin, and satiety signals. Following the last postprandial blood draw, we will serve another meal to measure ad libitum food intake. Our hypothesis is that subjects will have more appetite and consume more food after they have consumed the fructose-sweetened beverage for 8 days.
Primary outcome measures of this study will be the total energy consumed during the periods A, B, and C; the reduction in the intake of solid foods in periods A and B as compared to period C; and energy uptake during the ad libitum meal served on day 9 of each diet period. Secondary outcome measures will be resting energy expenditure and plasma concentrations of satiety and adiposity signals.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98195
- University of Washington General Clinical Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age: 18-25 years
- Body mass index: 20-25 kg/m2
- Weight stable to within 5 pounds for 6 months prior to entering the study
- Within 10 pounds of their lifetime maximum weight
- Ability to be admitted for 5 hours to the General Clinical Research Center of the University of Washington on three occasions
- Ability to provide informed written consent
- Willingness to consume only food provided by the Nutrition Research Kitchen of the University of Washington General Clinical Research Center for three periods of 8 days each
Exclusion Criteria:
- History of cardiovascular disease
- Presence of diabetes mellitus or impaired glucose tolerance (fasting glucose > 100 mg/dL)
- Presence of hypertension (blood pressure systolic/diastolic higher than 140/90)
- Presence of phenylketonuria
- Presence of fructose malabsorption or hereditary fructose intolerance
- Presence of another chronic or psychiatric illness
- Use of anabolic steroids, glucocorticoids, warfarin, beta-blockers, antidepressants, or lipid-lowering agents
- Use of antibiotic drugs within 3 months of enrollment into the study
- Use of tobacco products
- Pregnancy or female subject not using contraception
- Regular intense exercise (> 3 hour per week)
- Vegetarian or extreme dietary preferences
- Alcohol consumption of more than 2 drinks per day
- Presence of eating disorder
- History of frequent attempts at weight loss
- Currently dieting or in a weight control program
- Recent blood donation or enrolled in other research which requires blood sampling
- Presence or history of anemia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Fructose-sweetened beverage Subjects will be asked to drink 4 servings of a beverage sweetened with 100% fructose per day for 8 days, while consuming an ad libitum diet (same solid food for all three diet periods).
|
25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
|
Experimental: 2
Glucose-sweetened beverage Subjects will be asked to drink 4 servings of a beverage sweetened with 100% glucose per day for 8 days, while consuming an ad libitum diet (same solid food for all three diet periods).
|
25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
|
Placebo Comparator: 3
Beverage sweetened with a non-caloric sweetener Subjects will be asked to drink 4 servings of a beverage sweetened with a non-caloric sweetener per day for 8 days, while consuming an ad libitum diet (same solid food for all three diet periods).
|
25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Total energy consumed in the three diet periods.
Time Frame: 8 days in each period
|
8 days in each period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Resting energy expenditure
Time Frame: After 8 days of each dietary phase
|
Resting energy expenditure, as measured by indirect calorimetry.
|
After 8 days of each dietary phase
|
Fasting and postprandial plasma concentrations of satiety and adiposity signals.
Time Frame: After 8 days of each dietary phase
|
We will measure the fasting plasma concentration of leptin, adiponectin, ghrelin, insulin, glucagon-like peptide 1 (GLP-1), peptide YY (PYY), cholecystokinin (CCK), amylin, and oxyntomodulin, and the change in these endpoints in the two ours after a standardized meal has been consumed.
|
After 8 days of each dietary phase
|
Fasting and postprandial plasma lipid and lipoprotein concentrations.
Time Frame: After 8 days of each dietary phase
|
We will measure the fasting plasma concentrations of total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, and free fatty acids, as well as the changes in these endpoints in the two hours following a standardized meal.
We will also measure the fatty acid composition in the plasma phospholipids, and the free fatty acid fraction of plasma.
|
After 8 days of each dietary phase
|
Fasting plasma concentrations of inflammatory mediators.
Time Frame: After 8 days of each dietary phase
|
We will measure the fasting plasma concentrations of C-reactive protein (high sensitivity assay), interleukin-6 (IL-6), and the soluble tumor necrosis factor alpha receptors I & II.
|
After 8 days of each dietary phase
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Mario Kratz, Ph.D., University of Washington
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 28740-A
- 05-8515-A 03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
-
Consorcio Centro de Investigación Biomédica en...Maimónides Biomedical Research Institute of Córdoba; Instituto de Salud Carlos... and other collaboratorsActive, not recruiting
-
University of HoustonBaylor College of MedicineCompleted
Clinical Trials on Fructose
-
University of LausanneCompleted
-
Rockefeller UniversityThe Rogosin InstituteCompletedCardiovascular Disease | Diabetes | Elevated TriglyceridesUnited States
-
John SievenpiperCanadian Diabetes Association; The Physicians' Services Incorporated Foundation and other collaboratorsUnknownObesity | Overweight | Body Weight | Adiposity | Obesity, AbdominalCanada
-
University of TorontoCanadian Institutes of Health Research (CIHR); Canadian Diabetes Association; The Physicians' Services Incorporated FoundationUnknownCardiovascular Diseases | Stroke | Hypertension | Diabetes Mellitus, Type 2 | Gout | Metabolic Syndrome XCanada
-
Instituto Nacional de Cardiologia Ignacio ChavezCompletedMetabolic Syndrome | Overweight and Obesity | HyperuricemiaMexico
-
Touro University, CaliforniaRecruitingInsulin Resistance | Insulin Sensitivity | Pre DiabetesUnited States
-
University of CalgaryCompletedChronic Kidney DiseaseCanada
-
University of LausanneUniversity of BernCompletedMetabolic SyndromeSwitzerland
-
Hospital Moinhos de VentoCompleted
-
University of ZurichSwiss National Science FoundationCompleted